scholarly journals PCN239 REAL WORLD AVERAGE DOSE OF PARP INHIBITORS USED AS MAINTENANCE THERAPY FOR PLATINUM SENSITIVE RECURRENT OVARIAN CANCER

2020 ◽  
Vol 23 ◽  
pp. S65
Author(s):  
J. Perhanidis ◽  
P.H. Thaker ◽  
A. McBride ◽  
C. Hawkes
Keyword(s):  
Ovarian Cancer ◽  
Maintenance Therapy ◽  
Real World ◽  
Recurrent Ovarian Cancer ◽  
Parp Inhibitors ◽  
Average Dose ◽  
World Average ◽  
Platinum Sensitive

PARP inhibitors as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: Can we afford it?

2015 ◽  
Vol 137 ◽  
pp. 9 ◽  
Author(s):  
H.J. Smith ◽  
C.L. Walters Haygood ◽  
R.C. Arend ◽  
C.A. Leath ◽  
J.M. Straughn
Keyword(s):  
Ovarian Cancer ◽  
Maintenance Therapy ◽  
Recurrent Ovarian Cancer ◽  
Parp Inhibitors ◽  
Platinum Sensitive

scholarly journals 510 Niraparib outcomes in brca wild-type platinum sensitive recurrent ovarian cancer: a comparison of real-world data to the nova trial

2020 ◽  
Author(s):  
Douglas Cartwright ◽  
Patricia Roxburgh ◽  
Barbara Stanley ◽  
Jennifer Brown ◽  
Alistair Mclaren ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Real World ◽  
Recurrent Ovarian Cancer ◽  
Wild Type ◽  
Real World Data ◽  
World Data ◽  
Platinum Sensitive

scholarly journals Evaluation of niraparib 200 mg/d as maintenance therapy in recurrent ovarian cancer and associated thrombocytopenia in a real-world US setting

2019 ◽  
Vol 30 ◽  
pp. v411
Author(s):  
P. Thaker ◽  
K. Travers ◽  
C. Karki ◽  
R.P. Patel ◽  
C. Krebsbach ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Maintenance Therapy ◽  
Real World ◽  
Recurrent Ovarian Cancer
Sign in / Sign up

Export Citation Format

Share Document